224 related articles for article (PubMed ID: 20371721)
1. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Delgado JS; Mustafi R; Yee J; Cerda S; Chumsangsri A; Dougherty U; Lichtenstein L; Fichera A; Bissonnette M
Dig Dis Sci; 2008 Dec; 53(12):3055-64. PubMed ID: 18512153
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
8. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Chai H; Luo AZ; Weerasinghe P; Brown RE
Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Yang F; Jove V; Xin H; Hedvat M; Van Meter TE; Yu H
Mol Cancer Res; 2010 Jan; 8(1):35-45. PubMed ID: 20053726
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
13. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib exerts anti-glioma activity in vitro and in vivo.
Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
16. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
Roy Choudhury S; Karmakar S; Banik NL; Ray SK
Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Li F; Rajendran P; Sethi G
Br J Pharmacol; 2010 Oct; 161(3):541-54. PubMed ID: 20880395
[TBL] [Abstract][Full Text] [Related]
18. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis.
Prasad S; Pandey MK; Yadav VR; Aggarwal BB
Cancer Prev Res (Phila); 2011 Jul; 4(7):1084-94. PubMed ID: 21490133
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
20. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
